| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/11/2004 | EP1444980A1 Preventive or remedy for pruritus |
| 08/11/2004 | EP1444979A1 Pharmaceutical compositions comprising an NMDA receptor agonist or partial agonist for the treatment of movement disorders |
| 08/11/2004 | EP1444978A1 Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same |
| 08/11/2004 | EP1444977A1 Transdermal therapeutic delivery system with a butenolide |
| 08/11/2004 | EP1444974A2 Hair care composition containing a filmbuilding copolmer with a gradient, aerosol composition and process for treating hair |
| 08/11/2004 | EP1444520A2 Methods for monitoring amyotrophic lateral sclerosis |
| 08/11/2004 | EP1444347A2 METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs |
| 08/11/2004 | EP1444335A2 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| 08/11/2004 | EP1444315A1 Foamable antimicrobial formulation |
| 08/11/2004 | EP1444264A2 Methods and materials for targeting and affecting selected cells |
| 08/11/2004 | EP1444248A2 Novel anti-inflammatory androstane derivatives - 17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha |
| 08/11/2004 | EP1444247A2 Novel tibolone formulations |
| 08/11/2004 | EP1444237A1 Novel c-3 s/o- and s/n formaldehe acetal derivatives of cephalo sporins and their use as antibiotics |
| 08/11/2004 | EP1444236A1 Separation of regioisomers of metal phthalocyanines |
| 08/11/2004 | EP1444235A1 Reverse-turn mimetics and method relating thereto |
| 08/11/2004 | EP1444234A2 Deuterated pyrazolopyrimidinones and drugs containing said compounds |
| 08/11/2004 | EP1444233A2 A 2b? adenosine receptor antagonists |
| 08/11/2004 | EP1444232A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase |
| 08/11/2004 | EP1444231A1 Amine salts of an integrin receptor antagonist |
| 08/11/2004 | EP1444229A1 Pyrazole derivatives as psychopharmaceuticals |
| 08/11/2004 | EP1444228A2 Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors |
| 08/11/2004 | EP1444227A1 Thiazolyl substituted triazoles as alk5 inhibitors |
| 08/11/2004 | EP1444226A1 Compounds useful as reversible inhibitors of cysteine proteases |
| 08/11/2004 | EP1444225A2 Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists. |
| 08/11/2004 | EP1444224A2 3-substituted oxindole beta-3 agonists |
| 08/11/2004 | EP1444223A1 Aminopyrimidines and -pyridines |
| 08/11/2004 | EP1444220A1 Compounds and method for the treatment of overactive bladder |
| 08/11/2004 | EP1444219A1 Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor |
| 08/11/2004 | EP1444215A1 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| 08/11/2004 | EP1444212A1 Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds |
| 08/11/2004 | EP1444211A2 Quinazoline derivatives as antitumor agents |
| 08/11/2004 | EP1444210A1 Qunazoline derivatives as antitumor agents |
| 08/11/2004 | EP1444209A2 Mitotic kinesin inhibitors |
| 08/11/2004 | EP1444207A2 Substituted pyrazolyl-compounds for the treatment of inflammation |
| 08/11/2004 | EP1444206A1 Substituted benzo b azepin-2-one compounds |
| 08/11/2004 | EP1444204A1 Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
| 08/11/2004 | EP1444203A1 Cannabinoid receptor ligands |
| 08/11/2004 | EP1444202A1 Novel metalloproteinase inhibitors |
| 08/11/2004 | EP1444201A1 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors |
| 08/11/2004 | EP1444200A1 Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1 |
| 08/11/2004 | EP1444190A1 Combretastatin a-4 derivatives having antineoplastic activity |
| 08/11/2004 | EP1444010A2 Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| 08/11/2004 | EP1444009A1 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| 08/11/2004 | EP1443986A2 Drug delivery system for conscious sedation |
| 08/11/2004 | EP1443970A2 Promoters exhibiting endothelial cell specificity and methods of using same |
| 08/11/2004 | EP1443969A2 Non-inclusion cyclodextrin complexes |
| 08/11/2004 | EP1443967A1 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
| 08/11/2004 | EP1443966A1 Method of preventing or treating benign gynaecological disorders |
| 08/11/2004 | EP1443964A1 Photodynamic therapy for the treatment of hair loss |
| 08/11/2004 | EP1443962A2 Method for the treatment of cardiotoxicity induced by antitumor compounds |
| 08/11/2004 | EP1443950A2 A plant extract active as an immunostimulating agent |
| 08/11/2004 | EP1443948A1 Process for the preparation of anthocyanin-containing products |
| 08/11/2004 | EP1443946A2 Composition comprising soy and use thereof in the prevention and/or treatment of various diseases |
| 08/11/2004 | EP1443945A1 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis |
| 08/11/2004 | EP1443944A1 Pharmaceutical applications of hyaluronic acid preparations |
| 08/11/2004 | EP1443943A1 Process for reacting alkaloids and use of the reaction products in the preparation of medicaments |
| 08/11/2004 | EP1443942A1 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
| 08/11/2004 | EP1443941A2 Agents for treating lesions of the nervous system |
| 08/11/2004 | EP1443940A1 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof |
| 08/11/2004 | EP1443939A1 Compositions for treatment of postmenopausal female sexual dysfunction |
| 08/11/2004 | EP1443938A1 Dosage unit comprising a prostaglandin analog for treating constipation |
| 08/11/2004 | EP1443937A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| 08/11/2004 | EP1443935A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 08/11/2004 | EP1443934A1 Benzotriazepines as gastrin and cholecystokinin receptor ligands |
| 08/11/2004 | EP1443933A2 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
| 08/11/2004 | EP1443932A1 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
| 08/11/2004 | EP1443931A1 Methods for treating neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicaments |
| 08/11/2004 | EP1443930A1 Isoxazoline derivatives useful as antimicrobials |
| 08/11/2004 | EP1443929A2 Treatment of cns disorders using cns target modulators |
| 08/11/2004 | EP1443928A2 Treatment of neurodegenerative diseases and cancer of the brain |
| 08/11/2004 | EP1443927A2 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and other cancers |
| 08/11/2004 | EP1443926A1 Pyridine derivatives as nmda-receptor subtype blockers |
| 08/11/2004 | EP1443925A1 Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| 08/11/2004 | EP1443924A1 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body |
| 08/11/2004 | EP1443923A1 Hydroxy substituted amides for the treatment of alzheimer's disease |
| 08/11/2004 | EP1443922A1 Mch antagonists for the treatment of obesity |
| 08/11/2004 | EP1443921A1 PRODUCTION OF PURE STEREOISOMERS OF TRICYCLO 5.2.1.0 sp 2.6 /sp -DEC-9-YL XANTHOGENATE AND MEDICAMENTS THEREFROM |
| 08/11/2004 | EP1443920A2 Preparation for improving the action of receptors |
| 08/11/2004 | EP1443919A1 Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| 08/11/2004 | EP1443918A1 Calcium l-threonate for preventing or treating bone facture |
| 08/11/2004 | EP1443917A1 Tamsulosin tablets |
| 08/11/2004 | EP1443916A1 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor |
| 08/11/2004 | EP1443915A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
| 08/11/2004 | EP1443914A1 Method and pharmaceutical preparations for reducing the activity of cells |
| 08/11/2004 | EP1443913A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 08/11/2004 | EP1443911A1 Process for preparing quick dissolving, high loading ribavirin compositions |
| 08/11/2004 | EP1443910A1 Controlled release compositions for macrolide antimicrobial agents |
| 08/11/2004 | EP1443906A1 Method for the formation of ibuprofen crystals |
| 08/11/2004 | EP1443904A2 Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel |
| 08/11/2004 | EP1443903A2 Proliposomal drug delivery system |
| 08/11/2004 | EP1443902A2 Method for producing stable solutions of phenolic substances and resulting solutions |
| 08/11/2004 | EP1443900A2 Lipid carrier compositions with enhanced blood stability |
| 08/11/2004 | EP1443899A2 Bowel cleansing agent |
| 08/11/2004 | EP1443897A1 Carotenoid composition and method for protecting skin |
| 08/11/2004 | EP1443895A2 Utilization of sterols and their derivatives in cosmetic and dermatological preparations for uva protection |
| 08/11/2004 | EP1443892A1 Use of cationic surfactant as antimicrobial activity enhancer in deodorants and oral care |
| 08/11/2004 | EP1443861A2 Tumor targeted photodiagnostic-phototherapeutic agents |
| 08/11/2004 | EP1443820A1 Composition and method for treating graft-versus-host disease |
| 08/11/2004 | EP1365810A4 Calcium supplementation to reduce prostate cancer risk |
| 08/11/2004 | EP1365764A4 Oral pharmaceutical composition of cefpodoxime proxetil |